Literature DB >> 29397027

Hereditary palmoplantar keratodermas. Part II: syndromic palmoplantar keratodermas - Diagnostic algorithm and principles of therapy.

L Guerra1, M Castori2, B Didona3, D Castiglia1, G Zambruno4.   

Abstract

Hereditary palmoplantar keratodermas (PPKs) comprise a large and heterogeneous group of disorders characterized by persistent thickening of the epidermis at palmar and plantar surfaces. Clinical and genetic features of isolated and complex PPKs have been reviewed in part I of this 2-part review. Here we focus on clinical and molecular classification of syndromic PPKs which are recognized by additional extracutaneous manifestations, in particular deafness, specific mucosal lesions, cardiomyopathy, inborn errors of metabolism, involvement of internal organs or disorders of sexual development. Other genetic diseases, which may show palmoplantar involvement, such as selected subtypes of hereditary epidermolysis bullosa, various hereditary ichthyoses and other keratinization disorders, several ectodermal dysplasias and some multisystem genetic disorders, are also briefly summarized. PPK diagnosis is based on inheritance pattern, age at onset, morphology, distribution and severity of hyperkeratosis, pattern of additional dermatological and systemic manifestations and laboratory findings. Molecular analysis is at present the gold standard to confirm the diagnosis in PPK forms due to mutations in known causative genes. No specific and curative therapy is currently available for PPKs which highly impair patients' quality of life. Topical treatments are symptomatic and offer only temporary relief. Among systemic treatments, retinoids improve disease symptoms in the majority of patients.
© 2018 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2018        PMID: 29397027     DOI: 10.1111/jdv.14834

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Focal palmoplantar and gingival keratosis - A rare genodermatoses: Case report.

Authors:  Roberto Gerber-Mora; Martín Jajam-Maturana; Alejandra Fernández-Moraga; Rene Martinez-Flores
Journal:  J Clin Exp Dent       Date:  2020-11-01

2.  RSPO1-mutated keratinocytes from palmoplantar keratoderma display impaired differentiation, alteration of cell-cell adhesion, EMT-like phenotype and invasiveness properties: implications for squamous cell carcinoma susceptibility in patients with 46XX disorder of sexual development.

Authors:  Elena Dellambra; Sonia Cordisco; Francesca Delle Monache; Sergio Bondanza; Massimo Teson; Ezio Maria Nicodemi; Biagio Didona; Angelo Giuseppe Condorelli; Giovanna Camerino; Daniele Castiglia; Liliana Guerra
Journal:  Orphanet J Rare Dis       Date:  2022-07-19       Impact factor: 4.303

Review 3.  Five Functional Aspects of the Epidermal Barrier.

Authors:  Alain Lefèvre-Utile; Camille Braun; Marek Haftek; François Aubin
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

4.  Structural and functional foot disorders in patients with genodermatoses: a single-centre, retrospective chart review.

Authors:  Aldona Pietrzak; Bartlomiej Wawrzycki; Matthias Schmuth; Katarzyna Wertheim-Tysarowska
Journal:  Orphanet J Rare Dis       Date:  2022-02-16       Impact factor: 4.123

5.  A novel desmoplakin mutation causes dilated cardiomyopathy with palmoplantar keratoderma as an early clinical sign.

Authors:  V Karvonen; L Harjama; K Heliö; K Kettunen; O Elomaa; J W Koskenvuo; J Kere; S Weckström; M Holmström; J Saarela; A Ranki; T Heliö; K Hannula-Jouppi
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-05-06       Impact factor: 9.228

6.  Topical Selenium Sulfide for the Treatment of Hyperkeratosis.

Authors:  Philip R Cohen; Caesar A Anderson
Journal:  Dermatol Ther (Heidelb)       Date:  2018-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.